<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00325936</url>
  </required_header>
  <id_info>
    <org_study_id>CNL-MS-01</org_study_id>
    <secondary_id>SLIMS study</secondary_id>
    <nct_id>NCT00325936</nct_id>
  </id_info>
  <brief_title>The Effects of Cilnidipine on Metabolic Syndrome Improvement</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Superiority Clinical Study to Compare the Effects of Cilnidipine on Metabolic Syndrome Improvement With Nifedipine GITS in Hypertensive Patients With Metabolic Syndrome (Phase IV) [SLIMS]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abnormalities of glucose, insulin and lipoprotein metabolism are common in patients with
      hypertension, and these metabolic abnormalities are reported to be related to insulin
      resistance. Therefore, whenever treating such patients, antihypertensive agents that may have
      the added effect of improving insulin resistance should be selected. CinalongTM (Cilnidipine)
      is expected to improve metabolic syndrome as well as insulin resistance by its dual effects
      on L and N-type calcium (Ca) channels. In this study, the researchers investigate the effects
      of CinalongTM on insulin resistance and other metabolic related factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Multi-center, randomized, prospective, double blind, active control, parallel study

        -  Superiority study (Treatment group - Cilnidipine/Control group - Nifedipine)

        -  Measure the effects of Cinalong(TM) after 3 month and 12 month-application
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Homeostasis model assessment of insulin sensitivity (HOMA-IR)</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglyceride/HDL cholesterol ratio</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative insulin-sensitivity check index (QUICKI)</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting heart rate</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting norepinephrine</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in abdominal obesity</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglyceride</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cholesterol</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in trough SiSBP&amp;SiDBP</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood glucose</measure>
    <time_frame>after 3 month and 12 month treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Hypertension</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>parrallel design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilnidipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilnidipine</intervention_name>
    <description>10~20mg, qd, po for 3 months or 12 months.</description>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_label>Cilnidipine</arm_group_label>
    <other_name>Cinalong</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women, 30-65 years of age having essential hypertension with metabolic syndrome

          2. At Screening and Visit 1, blood pressure should be: sitting systolic blood pressure
             (SiSBP) &gt;=140 mmHg or sitting diastolic blood pressure (SiDBP)&gt;= 90 mmHg and two or
             more of the following criteria should apply.

               -  Abdominal obesity: waist circumference &gt;= 90 cm in men and &gt;= 80 cm in women

               -  Hypertriglyceridemia:. &gt;=150 mg/dl (1.695 mmol/l)

               -  Low HDL cholesterol: &lt; 40 mg/dl (1.036 mmol/l) in men and &lt; 50 mg/dl (1.295
                  mmol/l) in women

               -  High fasting glucose: &gt;= 110 mg/dl (6.1 mmol/l)

        Exclusion Criteria:

          1. Secondary hypertension

          2. Malignant hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Bae Park, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cheil General Hospital and Womenâ€™s Healthcare Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-hyun Lim, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Holy Family Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho-joong Youn, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University St Mary's Hospital (Yeouido)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yeong-geun An, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-su Kim, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong-yun Lee, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heon-sik Park, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ji-dong Seong, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In-ho Chae, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Se-joong Im, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Youngdong Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cheil general hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2006</study_first_submitted>
  <study_first_submitted_qc>May 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2006</study_first_posted>
  <last_update_submitted>August 26, 2008</last_update_submitted>
  <last_update_submitted_qc>August 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Choi, Jeongeun/Director</name_title>
    <organization>Boryung Pharmaceutical Co., Ltd</organization>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>Hypertension</keyword>
  <keyword>CCB</keyword>
  <keyword>cilnidipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Cilnidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

